Table 1 Clinical, virological, and immunological patient characteristics.

From: HCV-specific CD4+ T cells of patients with acute and chronic HCV infection display high expression of TIGIT and other co-inhibitory molecules

Infection status Age/Sex HLA-class II Genotype Peak VL (IU/ml) VL (IU/ml)* Peak ALT (U/l) ALT
(U/l)*
Longitudinal samples Outcome Therapy
aHCV 1 68/f DRB1*01:01, *14:01 1a / 4000000 / 51 yes cHCV/SVR peg-IFN/RBV (24 W)
aHCV 2 42/m DRB1*14:01, *15:01 1a 70000 70000 558 558 no cHCV /
aHCV 3 51/f DRB1*03:01, *15:01 2b 8000 8000 1548 798 no Sp. R /
aHCV 4 54/f DRB1*01:02,*03:01 3a 4000000 30000000 1273 1084 yes Sp. R /
aHCV 5 47/f DRB1*01:02, *15:01 n.a. Llod Llod 63 63 yes Sp. R /
aHCV 6 22/f DRB1*01:01, *03:01 1a 400000 30000 368 40 yes cHCV/SVR peg-IFN/RBV (24 W)
aHCV 7 32/m DRB1*13:02,*15:01 n.a. 70000 70000 1317 91 no Sp. R /
aHCV 8 44/m DRB1*01:01, *03:01 1a 30000000 90000 4316 1762 yes cHCV/SVR peg-IFN/RBV (24 W)
aHCV 9 38/f DRB1*03:01, 15:06 3 2070000 30500 521 115 no cHCV  
aHCV 10 39/m DRB1*04:01, *15:01 1a 18040000 140 2387 51 yes cHCV/SVR peg-IFN/RBV (24 W)
rHCV 11 38/m DRB1*11:01, *13:02 n.a. Llod Llod 32 22 no / /
rHCV 12 36/m DRB1*01:01, *11:01 n.a. Llod Llod 23 23 no / /
rHCV 13 36/m DRB1*07:01,*15:01 n.a. Llod Llod 66 43 no / /
rHCV 14 48/f DRB1*01:01,*- n.a. Llod Llod 15 10 no / /
rHCV15 51/f DRB1*01:01,*14:01 n.a. Llod Llod 94 48 no / /
rHCV 16 26/m DRB1*11:02, *12:01 n.a. Llod Llod 90 86 no / /
rHCV 17 44/m DRB1*01:01, *27:05 n.a. Llod Llod 84 20 no / /
rHCV 18 68/m DRB1*08:03, *11:01 n.a. Llod Llod 32 30 no / /
cHCV 19 65/m DRB1*11:01,*15:01 1a 1000000 800000 100 100 no / /
cHCV 20 60/f DRB1*04:01, *15:01 1b 9000000 9000000 68 54 no / /
cHCV 21 28/f DRB1*13:01, *15:01 1b 2000000 2000000 43 43 yes SVR Ledipasvir/Sofusbuvir (12 W)
cHCV 22 56/m DRB1*11:02, *15:01 1a 30000 10000 374 75 no / /
cHCV 23 63/f DRB1*07:01, *15:01 1b 10000000 2000000 138 54 yes SVR Ledipasvir/Sofosbuvir (12 W)
cHCV 24 43/m DRB1*04:04,*15:01 1b 6000000 5230000 208 128 yes SVR Ombitasvir/Paritaprevir/Ritonavir+Dasabuvir (12 W)
cHCV 25 43/f DRB1*13:01, *15:03 1a 8741517 2884373 43 43 no / /
cHCV 26 55/m DRB1*15:01, *13:01 3a 2775 2775 91 65 no / /
cHCV 27 40/f DRB1*03:01,*15:01 3 4330000 4330000 42 30 no / /
cHCV 28 39/f DRB1*04:08, *15:02 3 24300000 24300000 71 50 no / /
cHCV 29 46/m DRB1*07:01, *15:01 3 15900000 13300000 208 127 yes SVR Sofusbuvir/Velpatasvir (12 W)
tHCV 30 62/m DRB1*01:01 n.a. Llod Llod 58 58 no SVR peg-IFN/RBV (24 W)
tHCV 31 37/m DRB1*01:01, *07:01 3 25100000 26 319 43 no SVR Sofusbuvir/Velpatasvir (12 W)
tHCV 32 37/m DRB1*15:01, - 3 17800000 Llod 25 25 no SVR Sofusbuvir/Velpatasvir (12 W)
tHCV 33 52/m DRB1*01:01, *11:01 1a 2000000 Llod 272 107 no SVR peg-IFN/RBV (48 W)
tHCV 34 39/m DRB1*07:01, *11:01 3 850000 Llod 157 25 no SVR Sofusbuvir/Velpatasvir (12 W)